Cerus Corporation Celebrates World Blood Donor Day 2025

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025.

In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year’s theme, “Give blood, give hope: together we save lives” is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and expand donor eligibility, helping more people give, and more people receive the transfusions they need. The Company salutes the individuals, communities, and countries working together to make blood safety and availability a reality.

“A safe and reliable blood supply remains a cornerstone of every effective healthcare system around the globe, and one that would not be possible without the countless individuals that donate their time and blood. World Blood Donor Day is an opportunity to thank these individuals and to raise public awareness of the ongoing need for additional blood donations,” said Obi Greenman, Cerus’ President and Chief Executive Officer. “I am proud that Cerus is leading the development of pathogen reduction technologies for transfused blood components to help enable our blood center customers to deliver safe and effective blood components to patients.”

According to the World Health Organization (WHO), more than 118.5 million blood donations are collected annually around the world, with 40% of these donations collected in high-income countries that account for only 16% of the global population. A wide variety of patients regularly receive blood transfusion, including cardiovascular surgery, transplant surgery, massive trauma, cancer, obstetric, and childhood anemia patients.¹

In recognition of World Blood Donor Day, Cerus hosted a blood drive earlier this week at its company headquarters and encourages everyone to participate in supporting blood product availability in their local communities.

^1. https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250613811092/en/